All In Biotech

Drug Trial Radar · NCT06885021

Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults

Last checked: Nov 19, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 780 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

780

Planned (sponsor's estimate)

Start

Mar 28, 2025

Primary completion

May 30, 2026

Study completion Jun 30, 2026

Sponsor

Sponsor type
Industry
First posted
Mar 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3 Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults

Conditions

  • Overweight and Obesity

Interventions

  • HDM1002 200mg, oral, once daily, 52 weeksDrug

    HDM1002 200mg, oral, once daily, 52 weeks

  • HDM1002 400mg, oral, once daily, 52 weeksDrug

    HDM1002 400mg, oral, once daily, 52 weeks

  • HDM1002 placebo, oral, once daily, 52 weeksDrug

    HDM1002 placebo, oral, once daily, 52 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change From Baseline in Body WeightTime frame: 44weeks
  2. Percentage Change of Participants Achieving Weight Loss ≥ 5%Time frame: 44weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.